Lynozyfic

Pharma

After FDA rejection, Regeneron scores EU nod for Lynozyfic

Regeneron is off and running with its launch of linvoseltamab in Europe. In the U.S., the company is awaiting an FDA decision after a prior rejection.

Eric Sagonowsky Apr 28, 2025 10:12am